Oslo, Norway, 15 March 2023 – Targovax ASA (OSE: TRVX) today announces that an abstract describing its circular RNA platform has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, USA.
The abstract describes the advantage of protein expression utilizing Targovax´proprietary circAde vector system. By comparing protein expression from circRNA and mRNA-based vectors, it is shown that the circAde-system out-performs conventional mRNA-based designs, both in terms of protein expression level and durability. Persistent and prolonged protein expression in patients is expected to result in positive treatment outcomes. The results thus highlight the circAde platform’s potential for development of novel, more effective medicines for the treatment of cancer and other diseases.
The abstract has been released on the AACR website (https://www.abstractsonline.com/pp8/#!/10828/presentation/5271). The poster is scheduled for presentation Tuesday 18 April 2023 and will be available on Targovax’s website after the presentation.
|Poster title:||circAde: a circRNA-based system for prolonged and more effective treatment of cancer|
|Date and time:||Tuesday 18 April 2023, 13:30- 17:00 CDT / 20:30-24:00 CET|
|Location:||Orange County Convention Center, Orlando, Florida|
|Session title:||High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery|
|Poster number:||5335 / 17|
|Presenter:||Thomas Birkballe Hansen, VP Research, Targovax|
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immunological and safety profile in several indications, both as monotherapy and in combinations, and ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Targovax has also established a cutting-edge circular RNA (circRNA) program with the intent to develop next generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first generation products. In addition, Targovax has a KRAS immunotherapy program, with lead candidate TG01 due to enter clinical trials in an enhanced format in pancreatic cancer and multiple myeloma during early 2023. This provides Targovax with a rich pipeline of innovative future therapeutic candidates to follow ONCOS-102.